Literature DB >> 26971424

Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.

Chih-Wei Lee1, Hwa-Koon Wu1, Hung-Wen Lai2, Wen-Pei Wu3, Shou-Tung Chen4, Dar-Ren Chen4, Chih-Jung Chen5, Shou-Jen Kuo4.   

Abstract

PURPOSE: Ductal carcinoma in situ (DCIS) is a non-invasive cancerous breast lesion; however, from 10% to 50% of patients with DCIS diagnosed by core needle biopsy (CNB) or vacuum-assisted core biopsy (VACB) are shown to have invasive carcinoma after surgical excision. In this study, we evaluated whether preoperative clinicopathologic factors and breast magnetic resonance image (MRI) features are predictive of DCIS with invasive components before surgery.
MATERIALS AND METHODS: Patients comprised 128 adult women with a diagnosis of DCIS as determined by pathological analysis of CNB or VACB specimens and positive MRI findings who underwent breast surgery during the period January 2011 to December 2013 at the Changhua Christian Hospital. Clinicopathologic and breast MRI factors were compared between patients with postoperative pathology indicative of true DCIS and those with postoperative pathology showing DCIS with invasive components.
RESULTS: Of the 128 patients with a preoperative diagnosis of DCIS, 73 (57.0%) had postoperative histopathologic evidence of true DCIS and 55 (43.0%) showed evidence of DCIS with invasive components. Results of statistical analyses revealed that MRI evidence of a mass-like lesion (P=0.025), nipple-areolar complex (NAC) invasion (P=0.029), larger tumor volume (P=0.010), larger maximum measurable apparent diffusion coefficient (ADC) area (P=0.039), heterogenous or rim enhancement pattern (P=0.010), as well as immunohistochemical evidence of human epidermal growth factor receptor 2 (HER-2) overexpression (P=0.010) were predictive of DCIS with an invasive component in postoperative surgical specimens.
CONCLUSION: Invasive component should be considered in biopsy proven DCIS patients with preoperative MRI evidence of a mass-like lesion, nipple-areolar complex invasion, large tumor volume, a larger maximum measurable ADC area, or a rim or heterogenous enhancement pattern, as well as in patients with immunohistochemical evidence of HER-2 overexpression.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast magnetic resonance imaging (MRI); Ductal carcinoma in situ; Ductal carcinoma in situ with invasive components; Invasive breast cancer

Mesh:

Substances:

Year:  2016        PMID: 26971424     DOI: 10.1016/j.ejrad.2015.12.027

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  10 in total

1.  Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?

Authors:  Bibo Shi; Lars J Grimm; Maciej A Mazurowski; Jay A Baker; Jeffrey R Marks; Lorraine M King; Carlo C Maley; E Shelley Hwang; Joseph Y Lo
Journal:  Acad Radiol       Date:  2017-05-11       Impact factor: 3.173

2.  Usefulness of feature analysis of breast-specific gamma imaging for predicting malignancy.

Authors:  Eun Kyoung Choi; Jooyeon Jamie Im; Chang Suk Park; Yong-An Chung; Kijun Kim; Jin Kyoung Oh
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

Review 3.  Machine learning in breast MRI.

Authors:  Beatriu Reig; Laura Heacock; Krzysztof J Geras; Linda Moy
Journal:  J Magn Reson Imaging       Date:  2019-07-05       Impact factor: 4.813

4.  Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features.

Authors:  Bibo Shi; Lars J Grimm; Maciej A Mazurowski; Jay A Baker; Jeffrey R Marks; Lorraine M King; Carlo C Maley; E Shelley Hwang; Joseph Y Lo
Journal:  J Am Coll Radiol       Date:  2018-02-02       Impact factor: 5.532

5.  Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Authors:  Michael R Harowicz; Ashirbani Saha; Lars J Grimm; P Kelly Marcom; Jeffrey R Marks; E Shelley Hwang; Maciej A Mazurowski
Journal:  J Magn Reson Imaging       Date:  2017-02-09       Impact factor: 4.813

6.  Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)-A concordance comparison cohort analysis.

Authors:  Wen-Pei Wu; Hwa-Koon Wu; Chih-Jung Chen; Chih-Wie Lee; Shou-Tung Chen; Dar-Ren Chen; Chen-Te Chou; Chi Wei Mok; Hung-Wen Lai
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

7.  Can apparent diffusion coefficient (ADC) distinguish breast cancer from benign breast findings? A meta-analysis based on 13 847 lesions.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  BMC Cancer       Date:  2019-10-15       Impact factor: 4.430

8.  Impact of pre-operative breast magnetic resonance imaging on contralateral synchronous and metachronous breast cancer detection-A case control comparison study with 1468 primary operable breast cancer patients with mean follow-up of 102 months.

Authors:  Wen-Pei Wu; Chih-Yu Chen; Chih-Wei Lee; Hwa-Koon Wu; Shou-Tung Chen; Yu-Ting Wu; Ying-Jen Lin; Dar-Ren Chen; Shou-Jen Kuo; Hung-Wen Lai
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

9.  Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study.

Authors:  Gurdeep S Mannu; Emma J Groen; Zhe Wang; Michael Schaapveld; Esther H Lips; Monica Chung; Ires Joore; Flora E van Leeuwen; Hendrik J Teertstra; Gonneke A O Winter-Warnars; Sarah C Darby; Jelle Wesseling
Journal:  Breast Cancer Res Treat       Date:  2019-08-06       Impact factor: 4.872

10.  Predictive factors for the presence of invasive components in patients diagnosed with ductal carcinoma in situ based on preoperative biopsy.

Authors:  Kwan Ho Lee; Jeong Woo Han; Eun Young Kim; Ji Sup Yun; Yong Lai Park; Chan Heun Park
Journal:  BMC Cancer       Date:  2019-12-10       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.